TP53 and cancer: As demonstrated in Figures 1A, B, the most prominent cancer-related variations observed in this cohort were TTN mutations (found in 56% of tumors), followed by TP53 (51%), MUC16 (7%), and LRP1B (6%) mutations (Figure 1C).